Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon α for the Therapy of Minimal Residual Disease Following Hematopoietic Stem Cell Transplantation

NCT02185261 is registered in ClinicalTrials.gov with Peking University People's Hospital as lead sponsor.

NCT NCT02185261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02185261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon α for the Therapy of Minimal Residual Disease Following Hematopoietic Stem Cell Transplantation
Lead sponsor
Peking University People's Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
June 30, 2014
Completion date
June 30, 2021
Enrollment
81 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia